An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity
Lipid raft
DOI:
10.1371/journal.ppat.1011323
Publication Date:
2023-05-03T17:40:26Z
AUTHORS (19)
ABSTRACT
The severity of disease following infection with SARS-CoV-2 is determined by viral replication kinetics and host immunity, early T cell responses and/or suppression viraemia driving a favourable outcome. Recent studies uncovered role for cholesterol metabolism in the life cycle function. Here we show that blockade enzyme Acyl-CoA:cholesterol acyltransferase (ACAT) Avasimibe inhibits pseudoparticle disrupts association ACE2 GM1 lipid rafts on membrane, perturbing attachment. Imaging RNAs at single level using replicon model identifies capacity to limit establishment complexes required RNA replication. Genetic transiently silence or overexpress ACAT isoforms confirmed infection. Furthermore, boosts expansion functional SARS-CoV-2-specific cells from blood patients sampled during acute phase Thus, re-purposing inhibitors provides compelling therapeutic strategy treatment COVID-19 achieve both antiviral immunomodulatory effects. Trial registration : NCT04318314 .
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (84)
CITATIONS (10)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....